http___www.intimatemedicine.com.hr_seks-i-zdravlje_hoce-li-rak-vrata-maternice-uskoro-postati-stvar-povijesti__1.xml
1.1 2.1 2.2 3.1 3.2 4.1 4.2 5.1 5.2 5.3 6.1 7.1 7.2 7.3 8.1 9.1 10.1 11.1 12.1 12.2 12.3 13.1 14.1 14.2 14.3 14.4 15.1 16.1 16.2 16.3 16.4 16.5 16.6 17.1 18.1 18.2 19.1 20.1 20.2 20.3 20.4 21.1 22.1 23.1 24.1 24.2 25.1 26.1 26.2 26.3 27.1 28.1 29.1 29.2 30.1 30.2 31.1 32.1 32.2 32.3 33.1 33.2 33.3 34.1 35.1 36.1 37.1 38.1 39.1 40.1 41.1 42.1 43.1
ANTI CERVICAL CANCER JAB The new anticervical cancer vaccine that has been specifically developed to prevent most types of cervical cancer, which is caused by the Human Papilloma Virus (HPV). Cervical cancer is the second most common cause of death from cancer (after breast cancer) among young women (15 to 44 years) in Europe. In susceptible individuals, infection can cause abnormalities in the cells of the lining of the cervix such that they begin to multiply out of control to form pre-cancerous warts, which can then develop into tumours. The cervical cancer vaccine that provides effective anticervical cancer protection against 70% of cervical cancers. HPV is extremely commonplace and whilst not everyone suffers adverse reactions, more than 50% of the UK population carry or have at some time been infected by an HPV. Sexual contact is the primary method of transmission. Other symptoms of HPV infection can include genital warts, which are usually benign, but on rare occasions can turn malignant, causing, vulval, vaginal, penile and anal cancer. Benign genital warts can cause discomfort and bleeding during intercourse, and treatment by laser can be difficult and painful. The Vaccine protects against 90% of genital warts. For maximum protection, the optimum time to administer the cervical cancer vaccine is before commencement of sexual activity, although risk of infection persists for as long as a woman remains sexually active. The vaccine manufacturer, Sanofi Pasteur, has licensed the anticervical cancer vaccine for use in 9 to 26 year old females. However, the cervical cancer jab can also be given to women over 26 with a prescription. The clinic’s policy is to offer the cervical cancer jab vaccine to all girls and women aged 12 and over. Here are the answers to the most commonly asked questions: How many cervical cancer jab s / injections do I need? The anticervical cancer vaccination course is for three doses, the second and third injection being given at two and six months after the first injection. Does the vaccine stop all forms of cervical cancer? The Human Papilloma Virus has more than 100 different types. The vaccine cervical cancer jab protects against types 6, 11, 16 and 18. These are the four most common types, accounting for approximately 70% of cervical cancers (types 16 and 18) and 90% of genital warts cases (type 6 and 11). Will I still need to have cervical smears? Yes. The anticervical cancer vaccine prevents around 70% of cervical cancers. However, about 30% of cervical cancers are caused by HPV types not covered by the vaccine, which reinforces the importance of regular smear tests for early detection and cure. We can provide a cervical screening service undertaken by our qualified doctors. What is Cervical Screening? Cervical Screening is a method of preventing cancer by detecting and treating early abnormalities. The procedure involves our doctor inserting an instrument known as a speculum to open the vagina. A sample of cells is taken from the cervix using a spatula (or a swab) which is to then given to our labs for analysis. The procedure is quick and painless although some women may find it mildly uncomfortable. Please note that cervical screening is not a test for cancer. Like any procedure it is not foolproof, but can help early detection of cancerous cells. If I have already been exposed to one of the four types of HPV covered by the vaccine, will I still benefit from vaccination? Yes. Immunity will develop against the other three HPV types. Will the vaccine help me if I am older than the current recommended age group? Yes. The earlier the vaccination is given, the less chance there is of prior exposure to HPV. However, exposure to HPV infection may not occur until after 26, so the vaccine cervical cancer jab could be very beneficial for older women. This can be arranged through our clinics on a named patient prescription basis. Will the vaccine help if I have developed cervical cancer already? The cervical cancer vaccine is designed to protect your cells against initial HPV infection which ultimately can lead to abnormal pre-malignant cells and cancer. Can I pass the virus to other people I come into contact with after I have been vaccinated? The vaccine is a non infectious recombinant cervical cancer vaccine. In other words, it does not contain any live virus, but consists of virus like particles which stimulate the same immune response as the live virus. What are the side effects? About 1 in 10 people suffer minor side effects, which can include discomfort, swelling and redness at the injection site, and a fever. Occasionally, there can be some itching. Rarely, allergic skin rashes and a wheezy chest have occurred. Are there any contra-indications to vaccination? The vaccine should not be administered to anyone with a weakened immune system, any bleeding disorder, any allergy to the vaccine’s ingredients or a previous allergic reaction after the vaccine injection. The vaccine should not be given to anyone with a high fever. Please note that a mild fever, cough or cold are not valid reasons to delay vaccination. It is inadvisable to administer the vaccine during pregnancy and we will decline to treat anyone who is known to be pregnant or trying to conceive. It can be given in breast feeding women. Licensing The vaccine was licensed in the USA and Australia in June 2006 and received UK approval in September 2006. The licence is for use in 9 – 26 year olds as this is the age group in which clinical trials were performed. However it can be given to adults over 26 on a named patient prescription basis. The trend in the USA and Australia has been for the government to introduce vaccination for all 11 and 12 year olds. As yet, the NHS has not made any announcements on whether it will offer the vaccine and to whom. As the virus can be contracted at all ages, we recommend vaccination for all women. How do I book an appointment? Just call your nearest Immunisation and Medical Centre (see front page) and we will book your 3 appointments. Fee Payable for The Cervical Cancer Vaccine Registration* £ 50.00 First Vaccination £130.00 Second Vaccination £130.00 Third Vaccination £130.00 Cervical Screening service £ 50.00 * This is not payable if you or your child has registered as a patient with us previously. Relevant search terms = anticervical cancer , cervical cancer vaccine and cervical cancer jab
1.1 2.1 3.1 4.1 5.1 5.2 5.3 5.4 5.5 6.1 7.1 8.1 8.2 8.3 8.4 8.5 9.1 10.1 11.1 11.2 11.3 11.4 11.5 11.6 12.1 13.1 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 14.10 14.11 14.12 14.13 14.14 14.15 15.1
Hoće li rak vrata maternice uskoro postati stvar povijesti? Riječ je o pravoj revoluciji na području medicine, koja spriječava nastanak raka vrata maternice i genitalnih bradavica. Medicina je doživjela pravu prijelomnicu otkrićem cjepiva koje spriječava nastanak raka vrata maternice i genitalnih bradavica. Skrivena opasnost S HPV koji se prenosi s kože na kožu, a ne preko tjelesnih izlučevina, barem jednom u životu zarazi barem 50 % spolno aktivnih žena. Kod većine će zaraza vrlo brzo neopazice nestati, dok će kod drugih (približno 5 do 10 %) ostati duže vrijeme. Dugotrajna zaraženost može uzrokovati pojavu raka vrata maternice. Određena vrsta genotipa HPV-a odgovorna je za uzrokovanje raka vrata maternice, dok je druga vrsta genotipa HPV-a odgovorna za nastanak gotovo svih genitalnih bradavica ili kondiloma. Zaraženost HPV-om teško se prepoznaje, a veća mogućnost zaraze postoji kod onih žena koje sa spolnim odnosima započinju u mladim godinama (15 godina ili manje), kod onih koje imaju više spolnih partnera, kod pušačica i onih koje su HIV pozitivne. S HPV-om se zarazi više od 50% spolno aktivnih žena. Sada možete spriječiti nastanak raka vrata maternice U medicini je došlo do prijelomnice s pronalaskom cjepiva koje spriječava nastanak raka vrata maternice i nastanak genitalnih bradavica. Za otkrivanje raka vrata maternice vrlo su važni redovni ginekološki pregledi, koji uključuju uzimanje brisa. To je po učestalosti drugi rak u žena, od koga u nas godišnje oboli oko 2.250 žena, a od njega ih godišnje umre oko 850. Najčešće se pojavljuje u žena između 35. i 45. godina starosti. Upozoravajuće znakove možete otkriti i same, a među njih spadaju bolovi ili krvarenja tijekom spolnog odnosa, povećani vaginalni iscjedak iako nema upala, te krvave mrlje ili manja krvarenje između redovnih menstrualnih ciklusa. Kondom je loša zaštita od zaraze HPV-om, jer taj se virus prenosi s kože na kožu. Preventiva je još uvijek najbolja zaštita Vrlo veliku ulogu igraju redovni ginekološki pregledi i uzimanje brisa, jer pridonose pravovremenom otkrivanju i liječenju. Zaraza HPV-om spriječava se apstinencijom od spolnih odnosa ili cijepljenjem, koje se ubraja u najuspješnije preventivne mjere. Upotreba kondoma tijekom spolnog odnosa nije zadovoljavajuća zaštita, jer se virus prenosi s kože na kožu. PAP testom, odnosno uzimanjem brisa s vrata maternice, otkriva se jesu li stanice vrata maternice normalne ili su više ili manje bolesno izmijenjene (nenormalan rezultat PAP-a testa). U tom su slučaju potrebne dodatne pretrage. Naime, samim PAP testom se ne otkriva prisutnost HPV-a, već samo posljedice koje nastaju zbog njegovog djelovanja. Svaka četvrta mlada osoba u dobi od 9 do 26 godina zarazi se HPV virusom. Cjepivo je učinkovito gotovo 100 % Cjepivo spriječava nastanak stanica iz kojih se kasnije razvija rak vrata maternice, stanica iz kojih se kasnije razvija rak vanjskog spolovila kao i razvoj genitalnih bradavica. Cjepivo ne može prouzročiti zarazu ili bolesti što ih inače uzrokuje HPV. Cijepljenje se obavlja s tri odvojene doze cjepiva. Drugo se cijepljenje obavlja dva mjeseca nakon prvog, a treće četiri mjeseca nakon druge doze cjepiva. Važno je primiti sve tri doze cjepiva. U ovom su trenutku na raspolaganju podaci o učinkovitosti cijepljenja kod djevojaka u dobi od 9 do 26 godina. U toj se starosnoj skupini HPV-om zarazi svaki četvrti tinejdžer. Za sada su još uvijek u tijeku istraživanja na ženama i muškarcima starijim od 26 godina. U istraživanje učinkovitosti bilo je uključeno više od 20.000 mladih žena, a cjepivo je sa 100 postotnom učinkovitošću spriječilo nastanak teških predkancerogenih promjena i nastanak neinvazivnog raka vrata maternice. Cjepivo je također spriječilo 99% slučajeva genitalnih bradavica. Cijepiti se možete i kada ste već zaražena HPV-om. Popratni učinci cjepiva su minimalni. Na mjestu cijepljenja može se pojaviti crvenilo ili mala oteklina, a vrlo se rijetko može pojaviti i povećana tjelesna temperatura. Nakon cijepljenja i dalje treba odlaziti na redovite ginekološke preglede, a usluga cijepljenja se, za sada, plaća. Za točnije se informacije obratite svom ginekologu. ###SCROLLER###